Clinical Research Directory
Browse clinical research sites, groups, and studies.
Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)
Sponsor: Children's Hospital Medical Center, Cincinnati
Summary
The purpose of this study is to see if ruxolitinib, a Janus Kinase (JAK) 1/2 inhibitor, is safe for people who have acute skin graft versus host disease (GVHD) following allogenic hematopoietic stem cell transplantation (HSCT).
Official title: Efficacy of Topical Ruxolitinib in Acute Skin GVHD: A Pilot Study
Key Details
Gender
All
Age Range
2 Years - 35 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-10-01
Completion Date
2029-10
Last Updated
2026-09-03
Healthy Volunteers
No
Interventions
Ruxolitinib 1.5% cream
Ruxolitinib is a Janus Kinase (JAK) 1/2 inhibitor. JAKs are intracellular tyrosine kinases that play an important role in the development and function of immune cells that are involved in the pathogenesis of acute GVHD. For this study, ruxolitinib cream will be manufactured by Incyte and stored and distributed by the investigational pharmacy at CCHMC using standard operating procedures. Ruxolitinib 1.5% cream will be applied as a thin film topically twice a day to areas of erythroderma and pruritus. Participants and guardians will receive an informational instruction sheet describing the amount, frequency, and technique of applying the cream. Patients may continue to use standard of care GVHD prophylaxis and moisturizers.
Locations (1)
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States